Lyra Therapeutics (LYRA) Stock Forecast, Price & News

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Lyra Therapeutics in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" LYRA shares.
View LYRA analyst ratings or view top-rated stocks.

1 equities research analysts have issued twelve-month price objectives for Lyra Therapeutics' shares. Their LYRA share price forecasts range from $20.00 to $20.00. On average, they predict the company's stock price to reach $20.00 in the next twelve months. This suggests a possible upside of 580.3% from the stock's current price.
View analysts price targets for LYRA or view top-rated stocks among Wall Street analysts.

Lyra Therapeutics' stock was trading at $3.14 at the beginning of the year. Since then, LYRA stock has decreased by 6.4% and is now trading at $2.94.
View the best growth stocks for 2023 here.

Lyra Therapeutics saw a decrease in short interest in the month of May. As of May 15th, there was short interest totaling 17,700 shares, a decrease of 31.4% from the April 30th total of 25,800 shares. Based on an average daily trading volume, of 38,000 shares, the days-to-cover ratio is presently 0.5 days.
View Lyra Therapeutics' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 8th 2023.
View our LYRA earnings forecast.

Lyra Therapeutics, Inc. (NASDAQ:LYRA) issued its earnings results on Wednesday, March, 29th. The company reported ($0.36) EPS for the quarter, topping the consensus estimate of ($0.42) by $0.06. The firm had revenue of $0.01 million for the quarter, compared to analysts' expectations of $0.36 million. Lyra Therapeutics had a negative trailing twelve-month return on equity of 69.00% and a negative net margin of 5,032.86%.

Based on aggregate information from My MarketBeat watchlists, some companies that other Lyra Therapeutics investors own include Pfizer (PFE), DocuSign (DOCU), Intel (INTC), OPKO Health (OPK), Valero Energy (VLO), Advanced Micro Devices (AMD), CrowdStrike (CRWD), Gilead Sciences (GILD), Micron Technology (MU) and ONEOK (OKE).

(LYRA) raised $52 million in an IPO on Friday, May 1st 2020. The company issued 3,500,000 shares at $14.00-$16.00 per share. BofA Securities, Jefferies and William Blair acted as the underwriters for the IPO and BTIG was co-manager.

Lyra Therapeutics trades on the NASDAQ under the ticker symbol "LYRA."

Lyra Therapeutics' stock is owned by many different retail and institutional investors. Top institutional shareholders include Renaissance Technologies LLC (0.15%). Insiders that own company stock include C Ann Merrifield, Edward T Anderson, Harlan Waksal, Mukesh Mehta, Nbvm Gp, Llc and Perceptive Advisors Llc.
View institutional ownership trends.

Shares of LYRA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of LYRA stock can currently be purchased for approximately $2.94.

Lyra Therapeutics (NASDAQ:LYRA) has a market capitalization of $93.61 million and generates $1.36 million in revenue each year. The company earns $-55,280,000.00 in net income (profit) each year or ($1.63) on an earnings per share basis.

Lyra Therapeutics' mailing address is 480 ARSENAL STREET, WATERTOWN MA, 02472. The official website for the company is www.lyratherapeutics.com. The company can be reached via phone at 617-393-4600 or via email at laurence@gilmartinir.com.